Gastrointestinal Stromal Tumor Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, MOA, ROA, and Companies by DelveInsight

DelveInsight's "Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastrointestinal Stromal Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastrointestinal Stromal Tumor Market Forecast- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Gastrointestinal Stromal Tumor Market Report:
• The Gastrointestinal Stromal Tumor market size was valued approximately USD 454 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, among the EU4 countries and the UK, Germany recorded the highest market size for Gastrointestinal Stromal Tumors (GIST) therapy, reaching USD 33 million. Conversely, Spain had the smallest market size for GIST, estimated at around USD 17 million in 2023.
• Crenolanib, Bezuclastinib (CGT9486/PLX9486), OPDIVO (nivolumab) with or without YERVOY (ipilimumab), MEK162 combined with Imatinib Mesylate, along with other emerging therapies, are among the notable advancements in Gastrointestinal Stromal Tumor treatments. It is anticipated that several of these emerging products may become available on the market in the upcoming years.
• In 2023, the United States reported the highest number of incident cases of Gastrointestinal Stromal Tumors (GIST), totaling approximately 7,000 cases. This figure is projected to increase significantly in the near future, attributed to advancements in diagnostic and genetic testing methods. The US accounts for 43% of the total cases in the 7 major markets (7MM).
• According to DelveInsight's analysis, 15,140 GIST event instances are expected to occur overall in the 7MM by the year 2022. The US had the highest incident GIST cases in 2022 (6,528 cases), and this number is predicted to climb sharply in the near future due to improvements in diagnostic tests and genetic testing
• Based on mutation, the total incidence cases of GIST are divided into KIT mutation, PDGFRA mutation, BRAF mutation, and others. According to the evaluation, there will be 11,961 incident cases of KIT mutation, 1,629 incident cases of PDGFRA mutation, 137 incident cases of BRAF mutation, and 1,413 incident cases of other mutation in the 7MM in 2022
• Key Gastrointestinal Stromal Tumor Companies: Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
• Key Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
• The Gastrointestinal Stromal Tumor epidemiology based on gender analyzed that males accounted for a larger proportion of about 52% of total incident cases.

Get a Free sample for the Gastrointestinal Stromal Tumor Market Report: https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Gastrointestinal Stromal Tumor Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastrointestinal Stromal Tumor Epidemiology Segmentation:
• Total Prevalence of Gastrointestinal Stromal Tumor
• Prevalent Cases of Gastrointestinal Stromal Tumor by severity
• Gender-specific Prevalence of Gastrointestinal Stromal Tumor
• Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Epidemiology Forecast- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Gastrointestinal Stromal Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor market or expected to get launched during the study period. The analysis covers Gastrointestinal Stromal Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

Gastrointestinal Stromal Tumor Therapies and Key Companies
• TAS-116: Taiho Pharmaceutical
• Bezuclastinib: Cogent Biosciences, Inc./ Plexxikon
• Iclusig: Ariad Pharmaceuticals
• Cabozantinib: Exelixis
• THE-630: Theseus Pharmaceutical
• Famitinib: Jiangsu Hengrui Medicine
• PLX9486: Cogent Biosciences
• Nilotinib: Novartis
• HQP1351: Ascentage Pharma Group
• DS 6157: Daiichi Sankyo Company
• IDRX-42: IDRx, Inc.

Gastrointestinal Stromal Tumor Market Drivers
• Rich emerging Gastrointestinal Stromal Tumor pipeline
• Increasing incidence
• Understanding of pathophysiology
• Increased awareness
• Identification of solid tumor's treatment with NTRK gene fusions

Gastrointestinal Stromal Tumor Market Barriers
• Resistance against pharmacological therapies
• Clinical challenges in the management of disease
• High economic burden
• Side effects and adverse events after treatment

Scope of the Gastrointestinal Stromal Tumor Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastrointestinal Stromal Tumor Companies: Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
• Key Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gastrointestinal Stromal Tumor Unmet Needs, KOL's views, Analyst's views, Gastrointestinal Stromal Tumor Market Access and Reimbursement

To know more about Gastrointestinal Stromal Tumor companies working in the treatment market, visit @ Gastrointestinal Stromal Tumor Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Gastrointestinal Stromal Tumor Market Report Introduction
2. Executive Summary for Gastrointestinal Stromal Tumor
3. SWOT analysis of Gastrointestinal Stromal Tumor
4. Gastrointestinal Stromal Tumor Patient Share (%) Overview at a Glance
5. Gastrointestinal Stromal Tumor Market Overview at a Glance
6. Gastrointestinal Stromal Tumor Disease Background and Overview
7. Gastrointestinal Stromal Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Gastrointestinal Stromal Tumor
9. Gastrointestinal Stromal Tumor Current Treatment and Medical Practices
10. Gastrointestinal Stromal Tumor Unmet Needs
11. Gastrointestinal Stromal Tumor Emerging Therapies
12. Gastrointestinal Stromal Tumor Market Outlook
13. Country-Wise Gastrointestinal Stromal Tumor Market Analysis (2020-2034)
14. Gastrointestinal Stromal Tumor Market Access and Reimbursement of Therapies
15. Gastrointestinal Stromal Tumor Market Drivers
16. Gastrointestinal Stromal Tumor Market Barriers
17. Gastrointestinal Stromal Tumor Appendix
18. Gastrointestinal Stromal Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Biliary Stents Market: https://www.delveinsight.com/report-store/biliary-stents-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Chemotherapy Induced Febrile Neutropenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
• Chronic Inducible Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Refractory Gout Market: https://www.delveinsight.com/report-store/chronic-refractory-gout-market
• Clostridium Difficile Infections Cdi Market: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
• Colorectal Cancer Crc Market: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-market
• Contact Dermatitis Market: https://www.delveinsight.com/infographics/contact-dermatitis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
• Ehlers-danlos Syndrome Market: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market
• Gouty Arthritis Market: https://www.delveinsight.com/report-store/gout-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Hemorrhagic Cystitis Market: https://www.delveinsight.com/report-store/hemorrhagic-cystitis-market
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Higher-risk Chronic Myelomonocytic Leukemia Market: https://www.delveinsight.com/report-store/higher-risk-chronic-myelomonocytic-leukemia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Leber's Hereditary Optic Neuropathy Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Metachromatic Leukodystrophy Market Research Report: https://www.delveinsight.com/report-store/metachromatic-leukodystrophy-mld-market
• Neuroprosthetics Market: https://www.delveinsight.com/report-store/neuroprosthetics-market-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/pipeline-assessment-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.